CellCentric raises $120M in Series C funding, led by RA Capital Management and Forbion. The funds will advance Inobrodib, a new treatment for cancer and multiple myeloma.

May 19, 2025•about 2 months ago

Amount Raised

$120 Million

Round Type

series c

CambridgeBiotechnologyHealth Care

Investors

American Cancer SocietyBright EdgeAvego Bioscience CapitalForbionRa Capital Management

Description

CellCentric, a Cambridge-based clinical-stage biotechnology company, raised $120M in Series C funding. The round was led by RA Capital Management, with participation from Forbion and others. The funds will be used to advance Inobrodib, a treatment targeting cancer drivers. This oral capsule drug may help those unable to access other treatments.

Company Information

Company

CellCentric

Location

Cambridge, England, United Kingdom

About

CellCentric is a clinical-stage biotechnology company advancing Inobrodib, a new treatment for cancer, particularly multiple myeloma. This small molecule drug targets p300/CBP, reducing the expression of key cancer drivers, MYC and IRF4. It is delivered as an oral capsule, allowing patients to use it at home without the need for intensive monitoring. The drug has a favorable safety profile, making it suitable for those unable to access or tolerate other treatment options.

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

CellCentric raises $120M in Series C funding, led by RA Capital Management and Forbion. The funds will advance Inobrodib, a new treatment for cancer and multiple myeloma.

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information